{"DataElement":{"publicId":"5234432","version":"1","preferredName":"Chronic Graft Versus Host Disease Clinician Assessment Lung Response Category","preferredDefinition":"Text term that represents the chronic graft versus host disease response for lung based on clinician assessment.","longName":"CGVHD_CLIN_LUNG_CAT","context":"CCR","contextVersion":"1","DataElementConcept":{"publicId":"5233340","version":"1","preferredName":"Chronic Graft Versus Host Disease Clinician Assessment Lung Disease Response","preferredDefinition":"A syndrome of immunologically mediated tissue damage that may occur following an allogeneic transplant, and may affect multiple organs with manifestations similar to autoimmune diseases. The onset is usually within three years of transplantation or immunologic manipulation._An individual, such as a physician or nurse practitioner, who takes responsibility for a patient's care during an encounter._The final result of a determination of the value, significance, or extent of._One of a pair of viscera occupying the pulmonary cavities of the thorax, the organs of respiration in which aeration of the blood takes place. As a rule, the right lung is slightly larger than the left and is divided into three lobes (an upper, a middle, and a lower or basal), while the left has two lobes (an upper and a lower or basal). Each lung is irregularly conical in shape, presenting a blunt upper extremity (the apex), a concave base following the curve of the diaphragm, an outer convex surface (costal surface), an inner or mediastinal surface (mediastinal surface), a thin and sharp anterior border, and a thick and rounded posterior border._The pathologic and/or clinical changes that result from treatment. The changes may include eradication of detectable disease, stabilization of disease, or disease progression.","longName":"2512832v1.0:5233050v1.0","context":"CCR","contextVersion":"1","ObjectClass":{"publicId":"2512832","version":"1","preferredName":"Chronic Graft Versus Host Disease","preferredDefinition":"A graft versus host disease with symptoms appearing more than 100 days post-transplant.","longName":"C4981","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Chronic Graft Versus Host Disease","conceptCode":"C4981","definition":"A syndrome of immunologically mediated tissue damage that may occur following an allogeneic transplant, and may affect multiple organs with manifestations similar to autoimmune diseases. The onset is usually within three years of transplantation or immunologic manipulation.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":"NCI Thesaurus","workflowStatus":"RELEASED","registrationStatus":"Application","id":"1B8985BC-2113-374B-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2006-08-21","endDate":null,"createdBy":"UMLLOADER_AGNIS","dateCreated":"2006-08-21","modifiedBy":"SBREXT","dateModified":"2007-11-07","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"Property":{"publicId":"5233050","version":"1","preferredName":"Clinician Assessment Lung Disease Response","preferredDefinition":"An individual, such as a physician or nurse practitioner, who takes responsibility for a patient's care during an encounter.:The final result of a determination of the value, significance, or extent of.:One of a pair of viscera occupying the pulmonary cavities of the thorax, the organs of respiration in which aeration of the blood takes place. As a rule, the right lung is slightly larger than the left and is divided into three lobes (an upper, a middle, and a lower or basal), while the left has two lobes (an upper and a lower or basal). Each lung is irregularly conical in shape, presenting a blunt upper extremity (the apex), a concave base following the curve of the diaphragm, an outer convex surface (costal surface), an inner or mediastinal surface (mediastinal surface), a thin and sharp anterior border, and a thick and rounded posterior border.:The pathologic and/or clinical changes that result from treatment. The changes may include eradication of detectable disease, stabilization of disease, or disease progression.","longName":"C85499:C25217:C12468:C50995","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Clinician","conceptCode":"C85499","definition":"An individual, such as a physician or nurse practitioner, who takes responsibility for a patient's care during an encounter.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"3"},{"longName":"Assessment","conceptCode":"C25217","definition":"The final result of a determination of the value, significance, or extent of.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"2"},{"longName":"Lung","conceptCode":"C12468","definition":"One of a pair of viscera occupying the pulmonary cavities of the thorax, the organs of respiration in which aeration of the blood takes place. As a rule, the right lung is slightly larger than the left and is divided into three lobes (an upper, a middle, and a lower or basal), while the left has two lobes (an upper and a lower or basal). Each lung is irregularly conical in shape, presenting a blunt upper extremity (the apex), a concave base following the curve of the diaphragm, an outer convex surface (costal surface), an inner or mediastinal surface (mediastinal surface), a thin and sharp anterior border, and a thick and rounded posterior border.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Disease Response","conceptCode":"C50995","definition":"The pathologic and/or clinical changes that result from treatment. The changes may include eradication of detectable disease, stabilization of disease, or disease progression.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"3153AE96-34BF-D195-E050-BB89AD431F0E","latestVersionIndicator":"Yes","beginDate":"2016-04-25","endDate":null,"createdBy":"COOPERM","dateCreated":"2016-04-25","modifiedBy":"ONEDATA","dateModified":"2016-04-25","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ConceptualDomain":{"publicId":"2008550","version":"1","preferredName":"Disease Response","preferredDefinition":"the response criteria (includes RECIST and others) and associated documentation of disease.","longName":"DZ_RESP","context":"CTEP","contextVersion":"2.31","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B22C0651-216B-5273-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2002-12-19","endDate":null,"createdBy":"MSUPLEY","dateCreated":"2002-12-19","modifiedBy":"SBR","dateModified":"2003-10-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"3153AE96-34D0-D195-E050-BB89AD431F0E","latestVersionIndicator":"Yes","beginDate":"2016-04-25","endDate":null,"createdBy":"COOPERM","dateCreated":"2016-04-25","modifiedBy":"SBR","dateModified":"2016-06-06","changeDescription":"Created for CCR 16C0094 study as requested by P.Asangong. mc 4/25/16","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ValueDomain":{"publicId":"5234154","version":"1","preferredName":"cGvHD Lung Response Category","preferredDefinition":"A grouping of items based on some commonality or by user defined characteristics.","longName":"CGVHD_LUNG_CAT","context":"CCR","contextVersion":"1","type":"Enumerated","dataType":"CHARACTER","minLength":"11","maxLength":"17","minValue":null,"maxValue":null,"decimalPlace":null,"PermissibleValues":[{"value":"Complete Response","valueDescription":"Normal %FEV1, alkaline phosphatase, and Total bilirubin after previous elevation of 1 or more. If PFTs not available, NIH Lung Symptom Score 0 after previous involvement","ValueMeaning":{"publicId":"5234155","version":"1","preferredName":"Normal %FEV1, alkaline phosphatase, and Total bilirubin after previous elevation of 1 or more. If PFTs not available, NIH Lung Symptom Score 0 after previous involvement","longName":"5234155","preferredDefinition":"Either normal %FEV1, alkaline phosphatase, and total bilirubin after previous elevation of 1 or more or an NIH lung symptom score of 0 following GvHD involvement.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Lungs Complete Response GvHD","conceptCode":"C126707","definition":"Either normal %FEV1, alkaline phosphatase, and total bilirubin after previous elevation of 1 or more or an NIH lung symptom score of 0 following GvHD involvement.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"3155F840-9666-2B06-E050-BB89AD4375B2","latestVersionIndicator":"Yes","beginDate":"2016-04-25","endDate":null,"createdBy":"COOPERM","dateCreated":"2016-04-25","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"3155F840-967F-2B06-E050-BB89AD4375B2","beginDate":"2016-04-25","endDate":null,"createdBy":"COOPERM","dateCreated":"2016-04-25","modifiedBy":"ONEDATA","dateModified":"2016-04-25","deletedIndicator":"No"},{"value":"Partial Response","valueDescription":"Increase by 10% predicted absolute value of %FEV1. If PFTs not available, decrease in NIH Lung Symptom Score by 1 or more points","ValueMeaning":{"publicId":"5234156","version":"1","preferredName":"Increase by 10% predicted absolute value of %FEV1. If PFTs not available, decrease in NIH Lung Symptom Score by 1 or more points","longName":"5234156","preferredDefinition":"Either an increase by 10% predicted absolute value of %FEV1 or an NIH lung symptom score that has decreased by 1 or more points.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Lungs Partial Response GvHD","conceptCode":"C126721","definition":"Either an increase by 10% predicted absolute value of %FEV1 or an NIH lung symptom score that has decreased by 1 or more points.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"3155F840-9689-2B06-E050-BB89AD4375B2","latestVersionIndicator":"Yes","beginDate":"2016-04-25","endDate":null,"createdBy":"COOPERM","dateCreated":"2016-04-25","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"3155F840-96A2-2B06-E050-BB89AD4375B2","beginDate":"2016-04-25","endDate":null,"createdBy":"COOPERM","dateCreated":"2016-04-25","modifiedBy":"ONEDATA","dateModified":"2016-04-25","deletedIndicator":"No"},{"value":"Progression","valueDescription":"Decrease by 10% predicted absolute value of %FEV1. If PFTs not available, increase in NIH Lung Symptom Score by 1 or more points, except 0 to 1","ValueMeaning":{"publicId":"5234157","version":"1","preferredName":"Decrease by 10% predicted absolute value of %FEV1. If PFTs not available, increase in NIH Lung Symptom Score by 1 or more points, except 0 to 1","longName":"5234157","preferredDefinition":"Either a decrease by 10% predicted absolute value of %FEV1 or an NIH lung symptom score that has increased by 1 or more points, except 0 to 1.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Lung Progression GvHD","conceptCode":"C126733","definition":"Either a decrease by 10% predicted absolute value of %FEV1 or an NIH lung symptom score that has increased by 1 or more points, except 0 to 1.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"3155F840-96AC-2B06-E050-BB89AD4375B2","latestVersionIndicator":"Yes","beginDate":"2016-04-25","endDate":null,"createdBy":"COOPERM","dateCreated":"2016-04-25","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"3155F840-96C5-2B06-E050-BB89AD4375B2","beginDate":"2016-04-25","endDate":null,"createdBy":"COOPERM","dateCreated":"2016-04-25","modifiedBy":"ONEDATA","dateModified":"2016-04-25","deletedIndicator":"No"}],"ConceptualDomain":{"publicId":"2008550","version":"1","preferredName":"Disease Response","preferredDefinition":"the response criteria (includes RECIST and others) and associated documentation of disease.","longName":"DZ_RESP","context":"CTEP","contextVersion":"2.31","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B22C0651-216B-5273-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2002-12-19","endDate":null,"createdBy":"MSUPLEY","dateCreated":"2002-12-19","modifiedBy":"SBR","dateModified":"2003-10-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"RepresentationTerm":{"publicId":"2433877","version":"1","preferredName":"Category","preferredDefinition":"Category; used informally to mean a class of things.","longName":"C25372","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Category","conceptCode":"C25372","definition":"A grouping of items based on some commonality or by user defined characteristics.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":"NCI Thesaurus","workflowStatus":"RELEASED","registrationStatus":"Standard","id":"062E16DD-4D2F-16F1-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-11-28","endDate":null,"createdBy":"ALAIS","dateCreated":"2005-11-28","modifiedBy":"ONEDATA","dateModified":"2005-11-28","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"3155F840-9651-2B06-E050-BB89AD4375B2","latestVersionIndicator":"Yes","beginDate":"2016-04-25","endDate":null,"createdBy":"COOPERM","dateCreated":"2016-04-25","modifiedBy":"COOPERM","dateModified":"2016-05-09","changeDescription":"Created for CCR 16C0094 study as requested by P.Asangong. mc 4/25/16","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ClassificationSchemes":[{"publicId":"2008601","version":"1","longName":"C3D Domain","context":"CCR","ClassificationSchemeItems":[{"publicId":"2811685","version":"1","longName":"CCR","context":"CCR"}]},{"publicId":"2182125","version":"1","longName":"CCR Implementation","context":"CCR","ClassificationSchemeItems":[{"publicId":"2811673","version":"1","longName":"C3D","context":"CCR"}]},{"publicId":"2183535","version":"1","longName":"Clinical Trial Mgmt Systems","context":"NCIP","ClassificationSchemeItems":[{"publicId":"2812625","version":"1","longName":"CTMS C3D Adopter Sites","context":"NCIP"}]}],"AlternateNames":[],"ReferenceDocuments":[{"name":"Lungs","type":"Preferred Question Text","description":"Lungs","url":null,"context":"CCR"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Qualified","id":"31571635-3660-AE77-E050-BB89AD433717","latestVersionIndicator":"Yes","beginDate":"2016-04-25","endDate":null,"createdBy":"COOPERM","dateCreated":"2016-04-25","modifiedBy":"REEVESD","dateModified":"2016-05-02","changeDescription":"Created for CCR study 16C0094 as requested by P.Asangong. mc 4/25/16","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"}}